Ghana’s $109 million health deal refusal: who should control a nation’s medical records?

Ghana’s $109 million health deal refusal: who should control a nation’s medical records?

What is the true price of a nation’s health sovereignty when foreign aid arrives with strings attached? That is the uncomfortable question Accra has just answered — and the answer was no to $109 million.

Ghana turned down a proposed health agreement with the United States that would have delivered roughly $109 million in American funding over five years. The broader package was valued at about $300 million when Ghana’s own expected contributions were factored in. President John Dramani Mahama confirmed and explained the rejection during an appearance at the Council on Foreign Relations in New York on September 25.

His words struck a nerve.

“Who takes another country’s medical records?”

According to the Ghanaian president, the draft agreement would have required Ghana to hand over pathogen profiles and medical data to the United States. He also said the text obligated Ghana to provide counterpart funding and contained provisions about control over medical products entering the country.

For Mahama, those conditions were simply “humiliating.”

What Washington was actually asking for

The controversy deserves a closer look beyond the headline-grabbing quote.

Ghana did not reject a $100 million package just because it came from the United States. The sticking point was the conditions tied to the funding.

The proposed deal, worth approximately $300 million overall, would have brought Ghana about $109 million over five years. Arnold Kavaarpuo, executive director of Ghana’s Data Protection Commission and a participant in the negotiations, indicated that certain provisions would have allowed access to sensitive health data under circumstances that could potentially identify individuals. In his view, the scope of that access went far beyond what is normally required.

The BMJ also reported that the Ghanaian draft would have granted access to health data and pathogens to 16 American companies. The journal noted, however, that several clauses in the new US health agreements remain difficult to scrutinize publicly because not all negotiated texts have been released.

A nuance is therefore necessary: it would be excessive to claim the United States was demanding unrestricted access to “all Ghanaians’ medical records.” What is documented, however, are Ghanaian concerns about the extent of access to health data and pathogen information.

Why this data matters so much

Behind medical records lies a genuine question of power.

Health data reveals which diseases are circulating, where they are spreading, which populations are most exposed, and how outbreaks evolve.

Pathogen data can also carry considerable scientific value. It can contribute to research on vaccines, treatments, and surveillance of emerging epidemics.

That is precisely what fuels concerns among several African governments.

In February 2026, Jean Kaseya, director general of the Africa Centres for Disease Control and Prevention (Africa CDC), had already voiced serious concerns about data and pathogen-sharing provisions in the new US health agreements. Some agreements required rapid sharing of sensitive data without guaranteeing African countries access to treatments or vaccines that might result from that information.

Ghana is therefore not an isolated case.

Accra no longer wants to depend entirely on foreign aid

The rejection also comes in a particular context.

Since the suspension of a large portion of US aid programs, Ghana has been seeking to reduce its reliance on external funding. In February 2025, the Ghanaian presidency already estimated the shortfall caused by the suspension of USAID funding at $156 million, including $78.2 million directly affecting essential health programs.

The Mahama government is now pushing the idea of “health sovereignty.”

This direction was reinforced in September with the launch of the report A Sovereign Future for Health, presented as part of the Accra Reset initiative. The document proposes reducing Southern countries’ dependence on external funding and strengthening their own health systems.

Accra’s message is therefore relatively clear: Ghana wants to continue working with foreign partners, but on the basis of agreements it considers more balanced.

Another point of friction: medicines

The other element revealed by Mahama is particularly sensitive.

According to the president, the draft agreement provided that certain medicines and medical products supplied under the program would not be subject to controls by Ghana’s Food and Drugs Authority (FDA).

That claim has not been publicly confirmed in detail by the US government, which, when asked, said it does not comment on the details of bilateral negotiations.

But if that provision did indeed appear in the text presented to the Ghanaian government, it explains part of Accra’s firmness: for the authorities, health funding should not reduce the national regulator’s ability to control medical products used on its territory.

And the American response?

Washington has not publicly detailed the contested clauses.

A US State Department spokesperson said the United States does not disclose details of bilateral negotiations, while maintaining that Washington is still looking for ways to strengthen its partnership with Ghana.

This absence of a full public release of the text makes it impossible to settle certain essential questions.

Exactly what data would have been accessible?

To which American companies or institutions?

Under what circumstances could individuals have been identified?

How long would the data have been retained?

What legal guarantees would have protected Ghanaian patients?

On these points, public information remains incomplete.

Ghana opens a debate that goes beyond Ghana

The real issue in this affair may lie there.

For decades, many African health systems have depended on funding, medicines, equipment, and programs from abroad. These partnerships have saved lives and helped fight major diseases.

But the digital transformation of health is now changing the nature of cooperation.

Aid is no longer just about money, medicines, or equipment. It can also give access to a strategic resource: data.

And Ghana has just reminded the world that it intends to retain control of that resource.

John Mahama says his government rejected the draft after review by the Ministry of Health and deliberation by the Cabinet. He also says the decision had the support of the entire government and was made very quickly.

Ghana will now have to demonstrate that it can fill the abandoned funding gap without compromising its health programs.

But for Accra, the choice seems deliberate:

better to seek other partners than to conclude an agreement the government considers incompatible with health sovereignty and the protection of Ghanaians’ data.

The question Ghana is now putting to its foreign partners is simple:

When Africa receives aid to care for its people, must it also surrender control over information about those people?

The debate has probably only just begun.

By Claire Mvondo — Security and State Policy Expert